
Precision Biosciences (DTIL) Stock Forecast & Price Target
Precision Biosciences (DTIL) Analyst Ratings
Bulls say
Precision BioSciences is in a strong position for long-term growth, thanks to its innovative ARCUS platform which allows for sophisticated gene editing and has the potential to treat a variety of genetic diseases. The company's gene editing therapy for Duchenne muscular dystrophy (DMD) not only differentiates it from competitors, but also has the potential to be a game-changing treatment option for patients. Despite potential challenges in the administration of their hepatitis B therapy, Precision BioSciences's strong pipeline and promising trial results make it a company to watch in the gene editing space.
Bears say
Precision BioSciences is facing challenges in its gene editing therapies, as evidenced by the multiple doses needed to achieve cccDNA target engagement in the HBV viral genome elimination program, along with significant safety concerns including Grade 3 hypotension and serious adverse events. Additionally, the low success rate in the PBGENE-DMD functional dystrophin gene restoration program and potential manufacturing issues raise questions about the long-term viability and profitability of the company.
This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Precision Biosciences (DTIL) Analyst Forecast & Price Prediction
Start investing in Precision Biosciences (DTIL)
Order type
Buy in
Order amount
Est. shares
0 shares